- Home
- LPRO vs BDTX Comparison
LPRO vs BDTX Comparison
Compare LPRO & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LPRO | BDTX |
|---|---|---|
| Founded | 2000 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.2M | 171.9M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LPRO | BDTX |
|---|---|---|
| Price | $2.18 | $1.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $2.58 | ★ $9.67 |
| AVG Volume (30 Days) | 1.2M | ★ 2.1M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 96.46 | ★ 130.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.58 | N/A |
| Revenue Next Year | $14.01 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.18 | $1.78 |
| 52 Week High | $2.70 | $4.94 |
Technical Indicators
Market Signals| Indicator | LPRO | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.74 | 33.02 |
| Support Level | $2.03 | N/A |
| Resistance Level | $2.42 | $2.30 |
| Average True Range (ATR) | 0.19 | 0.14 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 42.00 | 5.41 |
Price Performance
Historical ComparisonAbout LPRO Open Lending Corporation
Open Lending Corp is a provider of lending enablement and risk analytics to credit unions, regional banks, finance companies and the captive finance companies of automakers (OEM captive finance companies). Through its flagship product, LPP, its customers, collectively referred to herein as automotive lenders or lenders, make automotive consumer loans to underserved near-prime and non-prime borrowers by harnessing its risk-based interest rate pricing models, powered by its proprietary data and real-time underwriting of automotive loan default insurance coverage from insurers.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.